Recent Updates — FLSC

Frazier Life Sciences Acquisition Corp. II consummated its initial public offering of 7,500,000 Class A ordinary shares at $10.00 per share, generating $75 million in gross proceeds. Simultaneously, the company completed a private placement of 300,000 shares to its sponsor for an additional $3 million. A total of $75 million was deposited into a U.S.-based trust account for the benefit of public shareholders. The company has not yet identified a specific business combination target and must complete one within 24 months or liquidate. Frazier Life Sciences Acquisition Corp. II is a blank check company formed to effect a merger, share exchange, asset acquisition, or similar business combination with one or more businesses in the life sciences sector.

Frazier Life Sciences Acquisition Corp. II consummated its initial public offering of 7,500,000 Class A ordinary shares at $10.00 per share on October 15, 2026, generating $75 million in gross proceeds. Simultaneously, the company completed a private placement of 300,000 founder shares to its sponsor for an additional $3 million. Jefferies LLC acted as the sole book-running manager for the offering. The net proceeds are held in a trust account pending the completion of an initial business combination with a target in the biotechnology sector. Frazier Life Sciences Acquisition Corp. II is a special purpose acquisition company focused on identifying and merging with promising biotech firms.